Stock-Based Compensation

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

The Company classifies stock-based compensation expense in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss, based on the department to which the recipient belongs. Stock-based compensation expense included in cost of goods sold and operating expenses during the three and nine months ended September 30, 2017 and 2016, was as follows:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Cost of goods sold	$	169	$	200	$	642	$	730
Operating expenses:
Research and development	328		389		911		1,187
Clinical and regulatory affairs	107		290		527		782
Marketing and sales	874		1,004		3,215		3,395
General and administrative	1,135		992		3,506		3,547
Total operating expenses	$	2,444	$	2,675	$	8,159	$	8,911
Total	$	2,613	$	2,875	$	8,801	$	9,641